Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing therapies for patients with cancer and diabetes who have limited treatment options, has released a video featuring a patient from a recent clinical trial. The patient participated in the phase 1 portion of Genprex’s Acclaim-1 study. During the video, the patient shares her experience, which includes extended Progression Free Survival (“PFS”) resulting from taking REQORSA(R), Genprex’s lead drug candidate. The patient is still taking the drug and is also still participating in the phase 1 portion of the Acclaim-1 clinical trial. According to the announcement, Genprex is working with world-class institutions to develop new drugs featuring the company’s pipeline of gene therapy candidates. Specifically, the company’s oncology program utilizes its proprietary nonviral ONCOPREX(R) Nanoparticle Delivery System, which Genprex believes is the first systemic gene therapy delivery platform used for cancer in humans. The company’s lead drug candidate is called REQORSA, an immunogene therapy for both non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). “While on REQORSA treatment, my doctor noted that the lung cancer lesions have not grown and there is no new growth,” said the NSCLC patient in the phase 1 portion of Acclaim-1. “I believe the REQORSA treatment has benefited my life and has increased my time.”
To view the full patient interview, visit https://ibn.fm/Ny9QU
To view the full press release, visit https://ibn.fm/OEQdj
About Genprex Inc.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, which currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, nonviral ONCOPREX(R) Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the tumor. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Both NSCLC clinical programs received a fast track designation from the Food and Drug Administration. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (“AAV”) vector to deliver Pdx1 (“Pdx1”) and MafA (“MafA”) genes to the pancreas. In models of type a diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type w diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, please visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
